We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific's Global Expansion: What's Behind the Growth?
Read MoreHide Full Article
Key Takeaways
BSX focuses on expanding its global presence, with EMEA, APAC and Latin America at 35% of 2025 revenues.
BSX is globalizing R&D from a largely U.S.-based model, accelerating product development worldwide.
BSX's Interventional Cardiology business generates nearly 70% of revenues from overseas markets.
Boston Scientific (BSX - Free Report) focuses on expanding its global presence to pursue growth opportunities in net sales and market share outside the United States. This includes Emerging Markets, defined as all countries, excluding the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada, which offer strong growth potentials owing to their economic conditions, healthcare sectors and global capabilities. In 2025, EMEA, APAC and Latin America collectively account for about 35% of total revenues.
During the 2025 Investor Day event, management expressed confidence in the company’s ability to continue outpacing the historical growth pace of these markets. Boston Scientific’s strategy to globalize research and development from being largely U.S.-based is reaping results in terms of product development. In the last few years, it has also expanded its manufacturing footprint in China, Costa Rica and Malaysia and also specializes in those plants. Infusion of AI and automation throughout the manufacturing network is also playing a key role. The company is also leveraging talents in countries like India and China by establishing functional centers of excellence to drive economic efficiency.
Particularly in China, the company is targeting revenues well above $1 billion in 2025. Boston Scientific’s China strategy rests on its talented and tenured team, investing in innovative Chinese companies that bolster its global portfolio and learning to thrive in the volume-based purchasing (VBP) environment, in contrast to several of its competitors that have pulled back.
In the Cardiovascular segment, Interventional Cardiology Therapies (ICTx) was highlighted as the company’s most global business with nearly 70% revenues generated overseas. Despite lower growth in the United States, Japan and Western Europe, strong development in the Emerging Markets has supported a double-digit growth rate in the business.
Updates From BSX’s Competitors: MDT and ISRG
This month,Medtronic (MDT - Free Report) has secured FDA approval for the Hugo robotic-assisted surgery (RAS) system for use in urologic surgical procedures. The development brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care. Medtronic has also begun the U.S. commercial launch of the MiniMed 780G system with Abbott’s Instinct sensor.
Intuitive Surgical’s (ISRG - Free Report) da Vinci Single Port surgical system was cleared by the FDA for use in inguinal hernia repair, cholecystectomy and appendectomy procedures. The development builds on its existing U.S. clearances in urology, colorectal, thoracic and transoral procedures.
BSX Price Performance, Valuation and Estimates
In the past three months, Boston Scientific shares have fallen 3.4% compared with the industry’s 5% drop.
Image Source: Zacks Investment Research
Boston Scientific has a forward one-year Price-to-Earnings (P/E) ratio of 27.50, lower than its median but above the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image: Bigstock
Boston Scientific's Global Expansion: What's Behind the Growth?
Key Takeaways
Boston Scientific (BSX - Free Report) focuses on expanding its global presence to pursue growth opportunities in net sales and market share outside the United States. This includes Emerging Markets, defined as all countries, excluding the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada, which offer strong growth potentials owing to their economic conditions, healthcare sectors and global capabilities. In 2025, EMEA, APAC and Latin America collectively account for about 35% of total revenues.
During the 2025 Investor Day event, management expressed confidence in the company’s ability to continue outpacing the historical growth pace of these markets. Boston Scientific’s strategy to globalize research and development from being largely U.S.-based is reaping results in terms of product development. In the last few years, it has also expanded its manufacturing footprint in China, Costa Rica and Malaysia and also specializes in those plants. Infusion of AI and automation throughout the manufacturing network is also playing a key role. The company is also leveraging talents in countries like India and China by establishing functional centers of excellence to drive economic efficiency.
Particularly in China, the company is targeting revenues well above $1 billion in 2025. Boston Scientific’s China strategy rests on its talented and tenured team, investing in innovative Chinese companies that bolster its global portfolio and learning to thrive in the volume-based purchasing (VBP) environment, in contrast to several of its competitors that have pulled back.
In the Cardiovascular segment, Interventional Cardiology Therapies (ICTx) was highlighted as the company’s most global business with nearly 70% revenues generated overseas. Despite lower growth in the United States, Japan and Western Europe, strong development in the Emerging Markets has supported a double-digit growth rate in the business.
Updates From BSX’s Competitors: MDT and ISRG
This month,Medtronic (MDT - Free Report) has secured FDA approval for the Hugo robotic-assisted surgery (RAS) system for use in urologic surgical procedures. The development brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care. Medtronic has also begun the U.S. commercial launch of the MiniMed 780G system with Abbott’s Instinct sensor.
Intuitive Surgical’s (ISRG - Free Report) da Vinci Single Port surgical system was cleared by the FDA for use in inguinal hernia repair, cholecystectomy and appendectomy procedures. The development builds on its existing U.S. clearances in urology, colorectal, thoracic and transoral procedures.
BSX Price Performance, Valuation and Estimates
In the past three months, Boston Scientific shares have fallen 3.4% compared with the industry’s 5% drop.
Image Source: Zacks Investment Research
Boston Scientific has a forward one-year Price-to-Earnings (P/E) ratio of 27.50, lower than its median but above the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.